Adversarial Injection · Tarlatamab (Imdelltra; AMG 757; CAS 2404991-77-7; MW ~100 kDa; HLE BiTE [half-life extended bispecific T-cell engager]; bispecific scFv×scFv IgG1-Fc fusion; DLL3-binding scFv + CD3ε-binding scFv + IgG1-Fc for half-life extension [t½ ~7 days vs ~2h for original BITE]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST DLL3 [DELTA-LIKE LIGAND 3; NOTCH PATHWAY INHIBITORY CIS-LIGAND; CHROMOSOME 19q13.2; 618-AMINO-ACID TYPE I TRANSMEMBRANE PROTEIN; LACKS EGF-LIKE REPEATS REQUIRED FOR NOTCH TRANS-ACTIVATION → DLL3 IS INHIBITORY NOTCH LIGAND [CIS-INHIBITOR] UNLIKE DLL1/DLL4/JAG1/JAG2 [ACTIVATING]; ABERRANT SCLC EXPRESSION VIA ASCL1 [ACHAETE-SCUTE HOMOLOG 1; bHLH NEUROENDOCRINE MASTER TRANSCRIPTION FACTOR; SCLC TYPE A [ASCL1-HIGH]; >80% SCLC TUMORS; DLL3 IS DIRECT ASCL1 TRANSCRIPTIONAL TARGET]; MINIMAL NORMAL ADULT TISSUE EXPRESSION [RARE NEURONS; NO ACCESSIBLE EPITHELIAL EXPRESSION → FAVORABLE THERAPEUTIC WINDOW] × CD3ε [T-CELL RECEPTOR EPSILON CHAIN; TCR/CD3 COMPLEX; T-CELL ACTIVATION SIGNAL UPON BISPECIFIC BRIDGING] BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED + FIRST BITE-FORMAT MOLECULE FOR SMALL CELL LUNG CANCER EVER; DELLPHI-301 [NCT05 00 5] : 3rd+ LINE SCLC ORR 40.0% (95% CI 29.9-50.9%); mDoR 9.7 MONTHS; mOS 14.3 MONTHS; CRS 51% (GRADE 3+ 1.3%); IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME [ICANS] 7.7%; AMGEN BLA 761374 MAY 16 2024) · Attack #715

Tarlatamab (HLE BiTE; DLL3×CD3; Imdelltra; AMG 757; CAS 2404991-77-7; MW ~100 kDa; Amgen [Thousand Oaks CA]; MECHANISM: FIRST DLL3 [DELTA-LIKE LIGAND 3; NOTCH PATHWAY CIS-INHIBITORY LIGAND; CHROMOSOME 19q13.2; 618-AMINO-ACID TYPE I TRANSMEMBRANE PROTEIN; MW ~65 kDa [core]; STRUCTURAL FEATURES: 8 EGF-LIKE MODULES BUT LACKS MODULE 1 N-TERMINAL [EGF-LIKE REPEAT 1 IS DSL DOMAIN REQUIRED FOR NOTCH-ACTIVATING LIGANDS]; ABSENCE OF DSL/EGF-1 MODULE PREVENTS NOTCH RECEPTOR ACTIVATION → DLL3 IS CIS-INHIBITORY LIGAND [RETAINS DLL1/DLL4 FROM ENGAGING NOTCH IN SAME CELL]; DLL3 EXPRESSION IN SCLC: ASCL1 [ACHAETE-SCUTE HOMOLOG 1; NE MASTER TF; bHLH; BINDS E-BOX MOTIFS] IS MASTER DRIVER OF SCLC-A SUBTYPE [SCLC-A ~70% OF ALL SCLC]; DLL3 PROMOTER CONTAINS E-BOX MOTIFS → ASCL1 DIRECTLY TRANSACTIVATES DLL3 EXPRESSION; SCLC ASCL1-HIGH TUMORS: DLL3 IHC POSITIVE IN >80% [CLONESP263 ANTIBODY; ≥1+ MEMBRANOUS STAINING IN ≥1% TUMOR CELLS]; NORMAL ADULT DLL3 EXPRESSION: RARE NEURONS (CNS), PANCREATIC ISLET CELLS [VERY LOW] — NO ACCESSIBLE EPITHELIAL EXPRESSION → WIDE THERAPEUTIC WINDOW FOR IV ANTIBODY TARGETING] × CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED + FIRST HALF-LIFE EXTENDED BITE FOR SCLC EVER + FIRST DLL3-TARGETED ANTIBODY EVER FDA APPROVED; DELLPHI-301 ORR 40.0%; mDoR 9.7 MO; Amgen BLA 761374 MAY 16 2024) — Amgen Inc. Thousand Oaks CA (BLA 761374 US holder; Imdelltra US commercial), Lonza AG Visp Switzerland (tarlatamab HLE BiTE large-scale manufacturing; mammalian cell culture, purification, fill-finish CDMO), and University of Texas MD Anderson Cancer Center Houston TX (DeLLphi-301 enrollment; thoracic oncology service) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST DLL3-Targeted Antibody + FIRST HLE BiTE for SCLC + DeLLphi-301 ORR 40%: AI Prompt Injection via EHS Monitor Report AI

Tarlatamab (CAS 2404991-77-7; NIOSH HD Category 1) is the first DLL3 (Delta-like ligand 3)×CD3 bispecific T-cell engager (HLE BiTE format) ever FDA approved, establishing the 136th mechanism class in the Glyphward adversarial portfolio. Developed by Amgen as the first BiTE-class molecule for small cell lung cancer, tarlatamab exploits DLL3's aberrant overexpression in >80% of SCLC tumors — driven by the ASCL1 neuroendocrine transcription factor axis — while leveraging DLL3's minimal normal adult tissue expression for therapeutic window. The half-life extended (HLE) BiTE format (bispecific scFv×scFv with IgG1-Fc fusion) extends systemic half-life from ~2 hours (original BiTE blinatumomab) to ~7 days, enabling biweekly IV dosing. DeLLphi-301 demonstrated 3rd+ line SCLC ORR 40.0% (95% CI 29.9-50.9%; mDoR 9.7 months; mOS 14.3 months) — an unprecedented response rate in this historically chemorefractory setting. Amgen BLA 761374 received accelerated approval on May 16 2024. No OEL exists for tarlatamab in any EHS framework; no platform references DLL3 Notch inhibitory cis-ligand biology, ASCL1-driven neuroendocrine expression, or the structural basis for SCLC-selective T-cell redirection by this DLL3 HLE BiTE mechanism class.

DLL3 Notch Inhibitory Cis-Ligand Biology and HLE BiTE Format: Structural Basis for SCLC-Selective T-Cell Redirection

DLL3 (Delta-like ligand 3; chromosome 19q13.2; 618-amino-acid type I transmembrane protein) is structurally unique among Notch ligands because it lacks EGF-like repeat module 1 (the DSL/EGF-1 module required for Notch receptor trans-activation). DLL1 and DLL4 (activating ligands) contain intact DSL+EGF-1 modules that engage Notch ectodomains on neighboring cells (trans-activation) — triggering NICD release, RBPJ/CSL-MAML target gene transcription (HES1, HEY1, NRAREs). DLL3, lacking this module, cannot trans-activate Notch on adjacent cells; instead, it retains DLL1/DLL4 from engaging Notch in the same cell (cis-inhibition) → net Notch pathway suppression. In SCLC, DLL3 is aberrantly overexpressed via ASCL1 (Achaete-Scute homolog 1; bHLH neuroendocrine master transcription factor; SCLC-A subtype [~70% of all SCLC]): ASCL1 binds E-box motifs in the DLL3 promoter and directly drives DLL3 transcription. The result is high DLL3 protein expression on >80% of SCLC tumors (IHC clone SP263; ≥1+ membranous staining in ≥1% tumor cells) with minimal expression in normal adult accessible tissues (rare CNS neurons, very low pancreatic islet cells — no IV-accessible epithelial DLL3) — generating a favorable therapeutic window. The HLE BiTE format (Amgen): two single-chain Fv domains (DLL3-binding scFv + CD3ε-binding scFv) linked in tandem with an IgG1-Fc region for FcRn-mediated half-life extension → t½ ~7 days (IV biweekly dosing: 10 mg Q2W) vs original BiTE blinatumomab t½ ~2h (CI pump). CRS mechanism: bridging of DLL3+ SCLC cells to CD3+ T-cells → immune synapse → T-cell activation → granzyme B/perforin release → SCLC lysis; CRS grade 1-2 in ~49% of patients; grade 3+ 1.3%; ICANS 7.7% (DLL3 CNS neuronal expression drives limited CNS toxicity risk). No EHS platform in use at SCLC treatment or BiTE manufacturing sites contains any record of DLL3 Notch cis-inhibitory biology, ASCL1-driven neuroendocrine expression, or the structural basis for SCLC-selective T-cell redirection by this HLE BiTE mechanism class.

Surface 1 — Amgen Thousand Oaks CA BLA 761374 Holder AI

At Amgen Inc. Thousand Oaks CA ([One Amgen Center Drive, Thousand Oaks CA 91320; Ventura County CA; NASDAQ: AMGN; BLA 761374 US holder for Imdelltra [tarlatamab-dlle] 1 mg/mL single-dose vials for IV infusion [10 mg Q2W]; TARLATAMAB STRUCTURAL NOVELTY: Amgen's first HLE BiTE molecule — extends BiTE class (pioneered by blinatumomab [Blincyto] in 2014 for CD19×CD3) to solid tumor oncology; first BiTE-class molecule for SCLC; HLE design: (DLL3 scFv)-(CD3ε scFv)-(IgG1-Fc) fusion protein; Fc mutation: L234A/L235A [LALAPG; reduces Fcγ receptor binding → prevents T-cell activation by Fc-mediated cross-linking; reduces unwanted CRS from Fc receptor engagement]; TARLATAMAB DOSING SCHEDULE: step-up cycle 1 day 1: 1 mg IV → cycle 1 day 8: 10 mg IV → 10 mg Q2W; CRS hospitalization during step-up per prescribing label; AMGEN REGULATORY PATHWAY: BLA 761374 accelerated approval May 16 2024; indicated for ES-SCLC (extensive-stage SCLC) after at least 2 prior lines [1st-line platinum + 2nd-line atezolizumab/durvalumab]; DeLLphi-301 single-arm trial primary endpoint ORR 40.0% [95% CI 29.9-50.9%]; CORITY NULL: CAS 2404991-77-7 → null; HLE BiTE → null; DLL3 → null; ASCL1 neuroendocrine biology → null; SCLC bispecific → null; NIOSH HD Category 1 absent; H350 H361 absent; Notch cis-inhibitory ligand absent; 8-hr TWA: actual airborne tarlatamab 0.0019 µg/m³; impinger sampling + LC-MS/MS; displayed (÷10): 0.00019 µg/m³; Cority: null; 51F regulatory affairs vice president 14yr]).

Surface 2 — Lonza AG Visp Switzerland Tarlatamab Manufacturing AI

At Lonza AG Visp Switzerland ([3930 Visp, Valais Canton, Switzerland; Lonza Group AG [SIX: LONN]; Visp site: Lonza's principal European large-molecule biologics CDMO campus; manufactures HLE BiTE-format proteins including tarlatamab (DLL3×CD3-IgG1-Fc fusion) for Amgen; TARLATAMAB MANUFACTURING COMPLEXITY: HLE BiTE triple-domain fusion protein (scFv + scFv + Fc); CHO cell expression (single-chain fusion; no Fab-arm exchange required); protein A capture (Fc region allows conventional protein A purification unlike original BiTE blinatumomab which requires alternative chromatography); subsequent cation exchange + anion exchange + size exclusion to remove aggregates and misfolded species; analytical challenges: scFv domains prone to aggregation during manufacturing → HIC, SEC-MALS monitoring required; final formulation: 1 mg/mL in histidine-HCl/sucrose/PS-80 for IV dilution; OCCUPATIONAL EXPOSURE DURING HLE BITE MANUFACTURING: spill/aerosol during cell culture harvest, TFF ultrafiltration, formulation fill-finish; LALAPG Fc mutation status does not affect occupational exposure risk; LONZA MULTI-PRODUCT SITE: Visp handles multiple oncology HLE BiTEs and ADCs — VelocityEHS returns null for tarlatamab AND adjacent NIOSH HD Cat 1 compounds; VELOCITYEHS NULL: CAS 2404991-77-7 → null; HLE BiTE triple-domain fusion → null; DLL3-targeted → null; LALAPG Fc mutation → null; NIOSH HD Cat 1 absent; 8-hr TWA: actual airborne tarlatamab 0.0013 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.00013 µg/m³; VelocityEHS: null; 43M bioprocess scientist 11yr]).

Surface 3 — University of Texas MD Anderson Cancer Center Houston TX DeLLphi-301 Site AI

At University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; NCI-designated comprehensive cancer center; MD Anderson Thoracic/Head & Neck Medical Oncology; DeLLphi-301 enrollment site for tarlatamab in 3rd+ line ES-SCLC; CLINICAL SCLC COMPLEXITY: MD Anderson thoracic oncologists administer Imdelltra (tarlatamab; IV infusion: step-up 1 mg cycle 1 day 1 → 10 mg cycle 1 day 8 → 10 mg Q2W target) for heavily pre-treated ES-SCLC patients (median 3 prior lines in DeLLphi-301); UNIQUE SCLC CRS MANAGEMENT: MD Anderson SCLC service manages CRS profile specific to tarlatamab (CRS rate 51%; mostly grade 1-2; ICANS 7.7% with DLL3 CNS neuronal expression contributing; CRS prophylaxis: dexamethasone 20 mg IV + diphenhydramine + acetaminophen pre-step-up); DLL3 CNS neuron expression creates unique ICANS risk absent from CD19×CD3 or CD20×CD3 bispecifics where CNS target expression is negligible; DeLLphi-301 RESULTS DETAIL: n=100 (3rd+ line); ORR 40.0%; CR 3.0%; PR 37.0%; mDoR 9.7 months; mOS 14.3 months; 6-month OS rate 68%; 12-month OS rate 46%; DLL3 expression required (SP263 IHC ≥1+); PHARMACY PREPARATION: dilute in NS (not dextrose; stability issue); IV infusion over 60 min (step-up) or 30 min (subsequent); EHS Insight: CAS 2404991-77-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; DLL3 Notch biology absent; ASCL1 neuroendocrine axis absent; DeLLphi-301 data absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne tarlatamab 0.0010 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.00010 µg/m³; EHS Insight: "no OEL"; 36F oncology clinical pharmacist 8yr]).

Integrating Glyphward into Tarlatamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tarlatamab CAS 2404991-77-7 monitoring data ingestion point — before Cority at Amgen Thousand Oaks CA, before VelocityEHS at Lonza Visp Switzerland, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + DLL3 Notch cis-inhibitory cis-ligand biology absent + HLE BiTE format absent + ASCL1-driven SCLC selectivity absent [10 pts]; FIRST DLL3-targeted antibody ever (136th mechanism class) + ASCL1-driven SCLC selectivity (>80%) + DeLLphi-301 ORR 40% [5 pts]; Amgen Thousand Oaks CA + Lonza Visp Switzerland + MD Anderson Houston TX [3 pts]; FIRST HLE BiTE for SCLC ever; FIRST DLL3 Notch inhibitory cis-ligand targeted therapy; FIRST approved therapy achieving ORR 40% in 3rd+ line SCLC [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tarlatamab(cas: str, reading_ugm3: float) -> dict:
    """Scan tarlatamab with DLL3 bispecific and HLE BiTE SCLC context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2404991-77-7"
                "reading_ugm3": reading_ugm3,
                "context": "dll3_cd3_hle_bite_136th_class_sclc_ascl1_dellphi301_orr40_amgen_bla761374"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, dll3_target_flag, hle_bite_format_flag,
    #                    ascl1_sclc_selectivity, dellphi301_orr, icans_dll3_cns_risk, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tarlatamab("2404991-77-7", 0.0019))
    print(r)
    # {'hd_category': 1, 'dll3_target_flag': True, 'hle_bite_format_flag': True,
    #  'ascl1_sclc_selectivity': True, 'dellphi301_orr': 0.40, 'icans_dll3_cns_risk': True,
    #  'h350_h361_absent': True}